Latest / The Series A Show with Fexingo: Early-Stage Funding, Pitch Decks, and Startup Milestones
Why Startups Are Using Pre-Filled Drug Trials
In this episode of The Series A Show, Lucas and Luna examine a surprising new tactic in biotech startup fundraising: pre-filled drug trials. Instead of starting from scratch, founders are buying or licensing partially completed clinical data from academic labs, contract research organizations, or even bankrupt competitors. The hosts break down a real-world case — a Series A round that closed in April 2026 for a startup called Synapsis Bio, which raised $18 million using data from a shelved Phase 1 trial originally run at Stanford. Lucas explains the economics: pre-filled trials can cut time…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.